<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03509012</url>
  </required_header>
  <id_info>
    <org_study_id>D933BC00001</org_study_id>
    <nct_id>NCT03509012</nct_id>
  </id_info>
  <brief_title>Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors</brief_title>
  <acronym>CLOVER</acronym>
  <official_title>A Phase I Multicenter Study of Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of
      durvalumab Â± tremelimumab in combination with chemoradiation in patients with advanced solid
      tumors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will initially treat up to approximately 300 patients with advanced solid tumors
      at approximately 30 sites, worldwide. The study will be composed of a dose-limiting toxicity
      (DLT) assessment phase (Part A) and an expansion phase (Part B).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2, 2018</start_date>
  <completion_date type="Anticipated">April 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 4, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>From first dose of durvalumab until 28 days after completion of radiation therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Adverse Events (AEs)</measure>
    <time_frame>From first dose of durvalumab up to 90 days after the last dose of study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From first dose until the date of objective disease progression or death, in the absence of progression at 12, 18 and 24 months, up to 4 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From first dose until death due to any cause through study completion, up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From first dose until disease progression, or the last evaluable assessment in the absence of progression, assessed up to 4 years.</time_frame>
    <description>Number (%) of patients with an overall response of complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best objective response (BoR)</measure>
    <time_frame>From first dose until disease progression, or the last evaluable assessment in the absence of progression, assessed up to 4 years.</time_frame>
    <description>The best response based on the overall visit responses from each RECIST 1.1 assessment or the last evaluable assessment in the absence of RECIST 1.1 progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>From first dose until disease progression, or death, in the absence of progression, assessed up to 4 years.</time_frame>
    <description>Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>From first dose until disease progression, at 18 weeks and 48 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>From first dose until disease progression or death, in the absence of progression at 12, 18 and 24 months, assessed up to 4 years.</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>HNSCC Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab + cisplatin with radiation in patients with locally advanced squamous cell carcinoma of the head and neck (HNSCC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab + cisplatin and etoposide with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab + carboplatin and paclitaxel with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigator's choice of carboplatin and pemetrexed OR cisplatin and pemetrexed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCLC Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCLC Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with limited-stage small-cell lung cancer (SCLC) should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCLC Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin. Note: Arm 3 will only be opened if the regimen in SCLC Arm 1 is safe and tolerable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCLC Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin Note: Arm 4 will only be opened if the regimen in SCLC Arm 2 is safe and tolerable.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>IV (intravenous)</description>
    <arm_group_label>HNSCC Arm 1</arm_group_label>
    <arm_group_label>NSCLC Arm 1</arm_group_label>
    <arm_group_label>NSCLC Arm 2</arm_group_label>
    <arm_group_label>NSCLC Arm 3</arm_group_label>
    <arm_group_label>SCLC Arm 1</arm_group_label>
    <arm_group_label>SCLC Arm 2</arm_group_label>
    <arm_group_label>SCLC Arm 3</arm_group_label>
    <arm_group_label>SCLC Arm 4</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>IV</description>
    <arm_group_label>SCLC Arm 3</arm_group_label>
    <arm_group_label>SCLC Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (dose level 4)</intervention_name>
    <description>IV</description>
    <arm_group_label>HNSCC Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (dose level 3)</intervention_name>
    <description>IV</description>
    <arm_group_label>SCLC Arm 1</arm_group_label>
    <arm_group_label>SCLC Arm 2</arm_group_label>
    <arm_group_label>SCLC Arm 3</arm_group_label>
    <arm_group_label>SCLC Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin (dose level 1)</intervention_name>
    <description>IV</description>
    <arm_group_label>NSCLC Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin (dose level 2)</intervention_name>
    <description>IV</description>
    <arm_group_label>NSCLC Arm 3</arm_group_label>
    <arm_group_label>SCLC Arm 1</arm_group_label>
    <arm_group_label>SCLC Arm 2</arm_group_label>
    <arm_group_label>SCLC Arm 3</arm_group_label>
    <arm_group_label>SCLC Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide (dose level 1)</intervention_name>
    <description>IV</description>
    <arm_group_label>NSCLC Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide (dose level 2)</intervention_name>
    <description>IV</description>
    <arm_group_label>SCLC Arm 1</arm_group_label>
    <arm_group_label>SCLC Arm 2</arm_group_label>
    <arm_group_label>SCLC Arm 3</arm_group_label>
    <arm_group_label>SCLC Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV</description>
    <arm_group_label>NSCLC Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>IV</description>
    <arm_group_label>NSCLC Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiation (dose level 1)</intervention_name>
    <description>radiation therapy</description>
    <arm_group_label>HNSCC Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiation (dose level 2)</intervention_name>
    <description>radiation therapy</description>
    <arm_group_label>NSCLC Arm 1</arm_group_label>
    <arm_group_label>NSCLC Arm 2</arm_group_label>
    <arm_group_label>NSCLC Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiation (hyperfractionated)</intervention_name>
    <description>radiation therapy</description>
    <arm_group_label>SCLC Arm 2</arm_group_label>
    <arm_group_label>SCLC Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (dose level 1)</intervention_name>
    <description>IV</description>
    <arm_group_label>NSCLC Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (dose level 2)</intervention_name>
    <description>IV</description>
    <arm_group_label>NSCLC Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiation (standard)</intervention_name>
    <description>radiation therapy</description>
    <arm_group_label>SCLC Arm 1</arm_group_label>
    <arm_group_label>SCLC Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  World Health Organization (WHO)/ECOG performance status of 0 or 1

          -  Body weight &gt;30 kg at enrollment and treatment assignment

          -  At least 1 measurable lesion, not previously irradiated

          -  No prior exposure to immune-mediated therapy (including therapeutic anticancer
             vaccines)

          -  For patients with oropharyngeal HNSCC HPV status has to be known

        Exclusion criteria:

          -  Patients with simultaneous primary malignancies or bilateral tumors

          -  Active or prior documented autoimmune or inflammatory disorders

          -  Brain metastases or spinal cord compression

          -  Active infection including tuberculosis, hepatitis B, hepatitis C, or human
             immunodeficiency virus (HIV; positive HIV 1/2 antibodies)

          -  Has a paraneoplastic syndrome (PNS) of autoimmune nature

          -  HNSCC cohort: Head and neck cancer that does not include unresectable, locally
             advanced cancer of oral cavity, larynx, oropharynx or hypopharynx. HNSCC of unknown
             primary are also excluded

          -  NSCLC and SCLC cohort: Mixed SCLC and NSCLC histology

          -  SCLC cohort: Extensive-stage SCLC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koto-ku</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sunto-gun</city>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>MÃ¡laga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>April 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Durvalumab</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>HNSCC</keyword>
  <keyword>NSCLC</keyword>
  <keyword>SCLC</keyword>
  <keyword>locally-advanced</keyword>
  <keyword>limited stage</keyword>
  <keyword>first line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_description>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

